Communiqués Lineage Cell Therapeutics, Inc.

Actions

LCTX

US53566P1093

Recherche biotechnologique et médicale

Marché Fermé - NYSE Autres places de cotation 22:00:00 08/07/2026			Varia. 5j.	Varia. 1 janv.
1,340 ^USD	+1,52%		+3,08%	-19,76%

13/05	Transcript : Lineage Cell Therapeutics, Inc., Q1 2026 Earnings Call, May 12, 2026
12/05	Lineage Cell Therapeutics, Inc. publie ses résultats pour le premier trimestre clos le 31 mars 2026	CI

Communiqués

06/07	Lineage Cell Therapeutics to Present at B. Riley Securities 2026 Mind, Muscle & Vision Healthcare Summit	BU
20/05	Cell-Based Therapies Poised to Disrupt Multi-Billion-Dollar Anti-Aging and Neurodegenerative Markets	AQ
12/05	Lineage Cell: Q1 Earnings Snapshot	AQ
12/05	Lineage Cell Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update	BU
05/05	Lineage Cell Therapeutics to Report First Quarter 2026 Financial Results and Provide Business Update on May 12, 2026	BU
04/05	OpRegen® 3 Year Results in Patients With GA Presented at Foundation Fighting Blindness Retinal Innovation Summit 2026	BU
13/04	Lineage Announces Formation of Scientific Advisory Board	BU
24/03	Lineage Launches New Cell Therapy Program in Corneal Endothelial Disease	BU
05/03	Lineage Cell Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update	BU
26/02	Lineage Cell Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results and Provide Business Update on March 5, 2026	BU
06/01	Lineage Takes Delivery of Gene-edited Hypoimmune Cell Line Under Partnership With Factor Bioscience	BU
05/01	Lineage Cell Therapeutics Issues Letter to Stockholders	BU
16/12	Beyond Insulin Pumps: Cell Therapies Unlock a $403B Cure Economy	PR
24/11	Lineage Cell Therapeutics : Achieves First Milestone Under Worldwide Collaboration Agreement with Genentech	PU
06/11	Lineage Cell: Q3 Earnings Snapshot	AQ
06/11	Lineage Cell Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Update	BU
30/10/25	Lineage Cell Therapeutics to Report Third Quarter 2025 Financial Results and Provide Business Update on November 6, 2025	BU
08/09/25	Lineage Cell Therapeutics Initiates Cell Transplant Program In Type 1 Diabetes	BU
02/09/25	Lineage Cell Therapeutics to Present at September 2025 Investor Conferences	BU
26/08/25	Lineage Announces Research Collaboration With William Demant Invest to Develop ReSonance™ (ANP1) for Hearing Loss	BU
12/08/25	Lineage Cell: Q2 Earnings Snapshot	AQ
12/08/25	Lineage Cell Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update	BU
05/08/25	Lineage Cell Therapeutics to Report Second Quarter 2025 Financial Results and Provide Business Update on August 12, 2025	BU
04/08/25	Lineage Announces Dosing of First Patient in New Clinical Study of OPC1 for Subacute and Chronic Spinal Cord Injury	BU
23/06/25	OpRegen® (RG6501) 36-Month Visual Acuity Results Featured at Clinical Trials at the Summit 2025	BU